FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia (Q43957365)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

0 references

phase III clinical trial

0 references

ceftaroline fosamil

1 reference

ChEBI release 2020-05-28

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

object named as

Donald E Low

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

1

object named as

Thomas M File

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

author name string

Paul B Eckburg

3

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

George H Talbot

4

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

H David Friedland

5

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Jon Lee

6

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Lily Llorens

7

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Ian A Critchley

8

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Dirk A Thye

9

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

FOCUS 1 investigators

10

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

language of work or name

0 references

publication date

1 April 2011

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Journal of Antimicrobial Chemotherapy

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

66 Suppl 3

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

iii19-32

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Rehospitalizations among patients in the Medicare fee-for-service program

1 reference

https://api.crossref.org/works/10.1093/JAC/DKR096

21 January 2018

BTS guidelines for the management of community acquired pneumonia in adults: update 2009

1 reference

https://api.crossref.org/works/10.1093/JAC/DKR096

21 January 2018

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

1 reference

https://api.crossref.org/works/10.1093/JAC/DKR096

21 January 2018

In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States

1 reference

https://api.crossref.org/works/10.1093/JAC/DKR096

21 January 2018

In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599.

1 reference

https://api.crossref.org/works/10.1093/JAC/DKR096

21 January 2018

Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains

1 reference

https://api.crossref.org/works/10.1093/JAC/DKR096

21 January 2018

A prediction rule to identify low-risk patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1093/JAC/DKR096

21 January 2018

Integrated Analysis of FOCUS 1 and FOCUS 2: Randomized, Doubled‐Blinded, Multicenter Phase 3 Trials of the Efficacy and Safety of Ceftaroline Fosamil versus Ceftriaxone in Patients with Community‐Acquired Pneumonia

1 reference

https://api.crossref.org/works/10.1093/JAC/DKR096

21 January 2018

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

1 reference

https://api.crossref.org/works/10.1093/JAC/DKR096

21 January 2018

Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk

1 reference

https://api.crossref.org/works/10.1093/JAC/DKR096

21 January 2018

Comparative analysis of two rates

1 reference

https://api.crossref.org/works/10.1093/JAC/DKR096

21 January 2018

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

1 reference

https://api.crossref.org/works/10.1093/JAC/DKR096

21 January 2018

Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1093/JAC/DKR096

21 January 2018

Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1093/JAC/DKR096

21 January 2018

Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1093/JAC/DKR096

21 January 2018

Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies

1 reference

https://api.crossref.org/works/10.1093/JAC/DKR096

21 January 2018

Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1093/JAC/DKR096

21 January 2018

CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

1 reference

https://api.crossref.org/works/10.1093/JAC/DKR096

21 January 2018

Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection

1 reference

https://api.crossref.org/works/10.1093/JAC/DKR096

21 January 2018

CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

1 reference

https://api.crossref.org/works/10.1093/JAC/DKR096

21 January 2018

Identifiers

10.1093/JAC/DKR096

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43957365&oldid=2104658188"